1 – 2 of 2
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2017
-
Mark
Ponezumab in mild-to-moderate Alzheimer's disease : Randomized phase II PET-PIB study
2017) In Alzheimer's and Dementia: Translational Research and Clinical Interventions 3(3). p.393-401(
- Contribution to journal › Article
- 2015
-
Mark
First Administration of the Fc-Attenuated Anti-β Amyloid Antibody GSK933776 to Patients with Mild Alzheimer's Disease: A Randomized, Placebo-Controlled Study.
(
- Contribution to journal › Article